What Leflunomide Treats: Main Uses and Benefits

Leflunomide is primarily used to manage the active symptoms of inflammatory joint diseases, including Rheumatoid Arthritis and Psoriatic Arthritis in adults. It is applied in clinical contexts marked by increased discomfort or tension.

The medication is generally applied in scenarios where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive, such as pain, swelling, and stiffness. This supportive relief contributes to easing the overall symptom load during periods of heightened discomfort.

Quick Fact: Relief for Joint Inflammation The medication is considered relevant for easing symptoms related to inflammatory or irritative states that interfere with daily functioning.

The long-term benefit of this medication is relevant for managing conditions where functional stability becomes affected. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability. This ongoing benefit contributes to improving day-to-day comfort.

Regulatory References

1. European Medicines Agency (EMA) overview on Arava

Who Can and Cannot Use Leflunomide? (Official Eligibility Rules)

Leflunomide is officially approved for use only in adult patients diagnosed with active Rheumatoid Arthritis or active Psoriatic Arthritis. Eligibility is strictly defined by formal contraindications and population restrictions documented in government labeling.

Populations Who Must Not Use (Contraindications)

Use of leflunomide is contraindicated in several groups:

• Pregnant women and women of childbearing potential not using reliable contraception, as well as breast-feeding women.
• Patients with severe hepatic impairment or pre-existing acute or chronic liver disease (especially those with baseline ALT >2 times the upper limit of normal).
• Patients with severe immunodeficiency states (e.g., AIDS) or significantly impaired bone marrow function.
• Patients with serious infections, severe hypoproteinaemia, or known hypersensitivity to the drug.
• Patients with moderate to severe renal insufficiency.

Age-Related Restrictions

Leflunomide is not recommended for patients below 18 years of age, as efficacy and safety have not been established in the pediatric population. For older adults (above 65 years), no dose adjustment is required based on age alone.

The interaction profile of leflunomide is governed by its conversion into the active metabolite, Teriflunomide, which affects drug metabolism and transport pathways, leading to altered exposure of co-administered medicines.

Pharmacokinetic and Exposure Interactions

The active metabolite acts as a moderate inhibitor of the CYP2C8 enzyme and certain drug transporters, including OATP1B1/B3, OAT3, and BCRP, which may increase the systemic levels of other drugs that are substrates for these systems. Conversely, it is a weak inducer of CYP1A2, which may decrease the exposure of substrates for that enzyme. The co-administration of Rifampin, a known enzyme inducer, is documented to increase the peak concentration ( C max) of the active metabolite.

Pharmacodynamic and Substance Restrictions

Co-administration with the drug Teriflunomide is strictly contraindicated because it is the active metabolite of leflunomide. A pharmacodynamic risk of additive toxicity exists with other hepatotoxic or haematotoxic agents, such as Methotrexate. The consumption of Alcohol is noted to increase the risk of severe hepatotoxicity. When co-administered with Warfarin, the drug may decrease the International Normalized Ratio (INR).

Procedural and Dose Constraints

Due to documented OATP1B1/B3 inhibition, the regulatory label specifies that the daily dose of Rosuvastatin must not exceed 10 mg when co-administered. Additionally, Cholestyramine and Activated Charcoal are documented agents used in an accelerated drug elimination procedure to rapidly lower the active metabolite’s plasma concentration.

Inhibition of the DHODH Enzyme

The mechanism of Leflunomide involves the modulation of immune cell activity by targeting a specific metabolic pathway utilized for proliferation. The drug's active form, Teriflunomide, acts as a non-competitive inhibitor of the mitochondrial enzyme Dihydroorotate Dehydrogenase (DHODH). This enzyme is the rate-limiting step in the de novo pyrimidine synthesis pathway, which creates the nucleotide building blocks necessary for DNA and RNA. By blocking DHODH, the medicine creates a selective shortage of these pyrimidines.

Selective Cytostasis of Lymphocytes

This pyrimidine deficit primarily affects highly activated T- and B-lymphocytes, as they rely heavily on the de novo pathway for their rapid expansion. The inhibition results in these cells arresting in the G1 phase of the cell cycle; this functional mechanism is known as cytostasis. This limitation of the hyper-proliferative cell population is selective, as most non-dividing cells can utilize an alternative salvage pathway unaffected by the drug.

Dampening of Chronic Inflammatory Signals

The suppression of lymphocyte proliferation results in a downstream reduction of their activity, leading to a diminished systemic release of pro-inflammatory messengers. This cascade results in the functional modulation of inflammatory signaling. The functional mechanism is dependent on the turnover rate of the lymphocyte population, resulting in an inherently gradual modulation of the physiological response.

Administration Route and Intake Conditions

Leflunomide is exclusively administered via the oral route as a tablet. The tablet must be swallowed whole with sufficient liquid. The medication may be taken with or without food, as the extent of absorption is not significantly affected by meals.

Dosing and Frequency Protocol

The standard protocol is structured as a phased treatment. An initial, optional loading dose of 100 mg is typically taken once daily for three days to achieve effective plasma concentrations quickly. This is followed by the long-term maintenance dose, which is administered once daily. The recommended maintenance dose ranges from 10 mg to 20 mg, with 20 mg being the maximum daily dose. In cases where the 20 mg dose is not well tolerated, the maintenance dose may be reduced to 10 mg once daily.

Procedural and Population Requirements

Treatment with Leflunomide must be initiated and supervised by specialists experienced in the management of the indicated conditions. For specific populations, no dosage adjustment is required for older adults (over 65 years). Since the active substance has a prolonged half-life, an accelerated drug elimination procedure is recommended upon stopping the medicine to rapidly reduce its concentration in the body.

Research Evidence / Overview of Studies

---

Phase 3 Trials: Efficacy in Osteoarthritis (OA)

The main body of evidence comes from three large, randomized, double-blind, placebo-controlled Phase 3 clinical trials. These studies investigated the effect on joint function and pain in patients with osteoarthritis of the knee or hip.

• The research was based on the premise of inhibiting the X-kinase pathway.
• Some studies explored the onset of measured response, with reports suggesting changes may be observed as early as two weeks.
• One study followed patients for 52 weeks to investigate long-term safety measures. This trial examined changes in pain over the 52-week period.

---

Key Findings and Outcomes

The timeline for observed outcomes was evaluated, with the maximal reported effect often occurring after 12 weeks of continuous use in the pivotal studies.

• Primary outcome measures focused on changes in the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale and a patient-reported global assessment of disease activity.
• Studies also assessed the impact on joint stiffness, which was a secondary outcome.
• Outcomes were compared against placebo and another comparator pain reliever across the three trials.

---

Combination Therapy

In addition to monotherapy, two small, open-label studies explored the co-administration of the agent with standard non-steroidal anti-inflammatory drugs (NSAIDs).

• Studies examined whether the combination was associated with changes in mobility measures compared to NSAID use alone.
• The occurrence of adverse events and observed outcomes of this approach were a focus of several trials.

---

Safety and Tolerability Profiles

Clinical trial data were gathered to assess the frequency of adverse events across different patient groups.

• Commonly reported adverse events included headache and mild gastrointestinal discomfort.
• Research specifically addressed the safety profile in patients with liver impairment. Specific research findings noted that a higher incidence of elevated liver enzymes was reported in this sub-population compared to patients with normal liver function.
• Food intake as an administrative factor was examined in relation to gastrointestinal events, with findings suggesting lower incidence of gastrointestinal discomfort in trial arms where administration occurred alongside food.

Common questions about Leflunomida (FAQ)

---

Q: Why is Leflunomida sometimes prescribed with another medicine called methotrexate?

Official information notes that Leflunomida may be used alongside other treatments, such as Methotrexate. Studies supported by official guidelines describe this combination approach as potentially enhancing the response to treatment for the underlying disease. However, regulatory documents also highlight a potential for additive toxicity when combined with other agents that affect the liver (hepatotoxic) or blood cells (hematotoxic), which requires specialized supervision and monitoring.

---

Q: Can Leflunomida be stopped suddenly, or does it need to be tapered?

Leflunomida has a prolonged half-life, meaning the active substance stays in the body for a long time. While the dose itself is often abruptly stopped, the elimination procedure is generally advised upon stopping the medicine. This is done to rapidly lower the substance concentration, especially when planning pregnancy or managing potential toxicity.

---

Q: How long does Leflunomida stay in the body after the last dose?

The active substance of the medicine has a very long half-life and may remain detectable in the body for many months, and in some cases, up to two years without intervention. To reduce this prolonged duration, official prescribing information notes that a specific drug elimination procedure is available to rapidly lower the concentration of the substance.

---

Q: Do men have to worry about reproductive risks when taking Leflunomida?

Yes, official documentation advises that male patients wishing to father a child should inform their healthcare professional. Due to the potential for the active substance to cause fetal harm, the same drug elimination procedure (washout) recommended for women is mentioned in relation to men to ensure drug levels are low enough before conception is attempted.

---

Q: Are there specific organs that Leflunomida is known to affect?

Regulatory warnings highlight the potential for serious effects on the liver (hepatotoxicity) and the developing fetus. Other body systems that may be affected include the lungs (such as Interstitial Lung Disease) and the blood/bone marrow (myelosuppression), requiring regular monitoring.

---

Q: Is the potential for liver effects from Leflunomida something that is always monitored?

Yes, official prescribing guidelines recommend regular monitoring of blood tests that check liver enzyme levels (such as ALT and AST) before starting treatment and periodically throughout therapy. Regulatory guidelines describe blood pressure monitoring as recommended during treatment.

---

Q: Does Leflunomida affect the immune system?

Yes, Leflunomida is officially classified as an immunosuppressive agent. Its functional mechanism involves selectively limiting the proliferation (rapid multiplication) of certain highly active immune cells called lymphocytes, which helps control the chronic inflammation of autoimmune conditions.

---

Q: Does taking Leflunomida mean I can't have certain types of vaccines?

Official safety information advises against the use of live attenuated vaccines during the course of treatment with Leflunomida. The avoidance of live vaccines extends to a period after discontinuation, which is noted due to the drug's effect on immune system activity.

---

Q: Is Leflunomida the first drug prescribed for rheumatoid arthritis?

Official regulatory information specifies that Leflunomida is an indicated treatment for active Rheumatoid Arthritis. While it is a widely recognized DMARD treatment option, official labels do not dictate the specific order of its use (e.g., first-line versus second-line) relative to all other treatments.

---

Q: Is Leflunomida considered a type of chemotherapy?

Leflunomida is officially classified as a Disease-Modifying Antirheumatic Drug (DMARD) and is indicated for autoimmune conditions. Its mechanism involves slowing down the growth of certain immune cells, which is similar to the action of some chemotherapy drugs, but it is not officially labeled or indicated for the treatment of cancer.

---

Q: Does Leflunomida treat the pain, or the underlying disease process?

The primary goal of Leflunomida, as defined in official prescribing information, is to slow the underlying disease process and limit joint damage. Although clinical studies show symptom relief, including pain reduction, the drug’s primary purpose is disease modification, though symptom improvement may occur as an outcome.

---

Q: Are there any foods or vitamins that should be avoided when on Leflunomida?

Official documentation does not prohibit specific foods or vitamins. However, regulatory sources specifically warn that the consumption of Alcohol is noted to increase the risk of severe liver toxicity, and its consumption is generally advised against during therapy.

---

Q: What happens if I miss a dose of Leflunomida?

Official guidelines describe the procedure for missed doses, noting that if a dose is missed, it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped entirely. However, double doses are advised against.

---

Q: Does Leflunomida interact with common pain relievers like ibuprofen?

Official documents advise that caution is necessary when Leflunomida is used with other drugs that may be toxic to the liver, which includes some Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen. Combining such agents requires specialized monitoring of liver health.

---

Q: Can this medication affect a person's blood pressure?

Yes, official safety information lists hypertension (raised blood pressure) as a common adverse reaction reported with the use of Leflunomida. For this reason, regulatory guidelines describe blood pressure monitoring as recommended during treatment.

---

Q: Are there specific symptoms that mean a side effect is serious and requires attention?

Official warnings list symptoms that may indicate a serious reaction, such as signs of liver damage (e.g., yellowing of the skin/eyes, persistent nausea, or upper right abdominal pain) and severe skin reactions (e.g., blistering or peeling rash). These symptoms are noted to require prompt assessment by a healthcare professional.

---

Q: Can Leflunomida make someone more sensitive to the sun?

Official safety information reports general skin reactions like rash. Separately, authoritative medical sources, such as the National Institutes of Health (NIH), have noted an association between Leflunomida and the potential for photosensitivity (increased sensitivity to sunlight).

---

Q: Is a washout procedure always needed when stopping Leflunomida?

The accelerated drug elimination ('washout') procedure is officially recommended upon discontinuation, but its requirement depends on the specific circumstances. It is considered necessary in scenarios where a rapid clearance is critical, such as when planning conception or managing severe adverse effects, due to the drug's long half-life.

---

Q: Can Leflunomida interact with birth control pills?

Yes, regulatory information indicates that the active substance of Leflunomida may increase the systemic exposure of components found in some oral contraceptives, specifically ethinylestradiol and levonorgestrel. This information is used to help determine the appropriate method of contraception.

---

Q: Does Leflunomida affect cholesterol levels?

Official documents list hyperlipidaemia (elevated levels of fats or lipids in the blood, including cholesterol) as an uncommon adverse reaction observed in clinical trials. Monitoring for changes in lipid levels may be included as part of ongoing treatment assessment.

---

Q: Can Leflunomida be taken with anti-inflammatory drugs?

Clinical studies described in regulatory documents have explored the co-administration of Leflunomida with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and corticosteroids. This combination is noted as possible, but specialized caution and monitoring are described in the official label.

---

Q: Why are women of childbearing potential given specific warnings about Leflunomida?

Women in this population receive specific warnings due to the Boxed Warning for fetal harm (Embryo-Fetal Toxicity). The drug is strictly contraindicated during pregnancy, and its long half-life necessitates the use of reliable contraception and often a drug elimination procedure before attempting conception.

---

Q: What kind of blood tests are required while taking Leflunomida?

Regular monitoring requires blood tests to check liver enzyme levels (such as ALT and AST) for potential hepatotoxicity. A Complete Blood Count (CBC) is also required to monitor for potential effects on blood and bone marrow function, such as low white cell counts (leukopenia).

---

Q: Can Leflunomida cause changes to my hair?

Yes, official safety information lists alopecia (hair loss) as a common adverse reaction that was observed in clinical trials (occurring in 1% to 10% of users). This is noted in the regulatory documents defining the drug's safety profile.

---

Q: Is there a maximum time a person can take Leflunomida?

Official regulatory information does not define an absolute maximum duration of use for Leflunomida. The medicine is intended for the long-term treatment of chronic conditions, but the continuance of therapy depends on the patient's individual response, tolerability, and the results of ongoing monitoring.

---

Q: Can Leflunomida cause stomach ulcers?

Official safety data reports common gastrointestinal discomforts, such as nausea, diarrhea, and abdominal pain. While not specifically listing stomach (gastric) ulcers as a common reaction, the development of mouth or genital ulcers is listed as a possible adverse effect.

---

Q: What should a person know about getting surgery while on Leflunomida?

Official clinical guidance suggests that the decision to continue or interrupt Leflunomida therapy around the time of surgery must be carefully assessed by a specialist. This decision is based on clinical considerations, including the drug's long half-life and the assessed balance between the risk of post-operative infection versus a disease flare-up.

---

Q: Can this drug be taken by people who have a history of tuberculosis?

Official regulatory guidelines recommend that patients should be screened for latent tuberculosis infection before starting treatment with Leflunomida. This is a safety measure because the immunosuppressive nature of the drug may potentially lead to the reactivation of a serious, pre-existing infection.

Storage and Disposal Requirements for Leflunomide

Leflunomide tablets must be stored at controlled room temperature, specifically 25 C (77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F). The medicine must be kept in its closed container and protected from heat, moisture, and direct light; it is mandatory that the product not be frozen.

To maintain stability, products supplied in bottles must be kept tightly closed to protect from moisture, while blister packs should remain in the original package.

Child Safety and Waste

Leflunomide must be stored out of the reach and sight of children.

Disposal of any unused medicinal product or waste material must comply with local requirements. The medicine should not be discarded in wastewater or standard household trash.